Source:http://linkedlifedata.com/resource/pubmed/id/11425552
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
2001-6-26
|
pubmed:abstractText |
3,5-Disubstituted-phenylcyanoguanidines have been identified as activators of SUR1/Kir6.2 potassium channels and as potent inhibitors of insulin release from pancreatic beta cells in vitro.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0960-894X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
9
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1749-52
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading | |
pubmed:year |
2001
|
pubmed:articleTitle |
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
|
pubmed:affiliation |
Discovery and Development, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark.
|
pubmed:publicationType |
Journal Article,
In Vitro
|